Biostem Tech Stock Price, News & Analysis

BioStem Technologies Inc. (OTC Pink: BSEM) is making significant strides in the MedTech sector with innovative wound-care treatments. The company's focus on regenerative medicine and placental tissue allografts has led to impressive developments, including the prioritization of its BioRetain technology patent by the U.S. Patent Office. BioStem's product lineup, including VENDAJE™ and AMNIOWRAP2, has shown promising results in wound care studies.

The company reported a remarkable 1,355% year-over-year increase in Q4 net revenue to $11.5 million, with a gross profit margin of 95%. BioStem's strategic initiatives and product launches have expanded its market reach, positioning it to capitalize on the growing global wound care market, projected to reach $27.2 billion by 2027.

BioStem Technologies (OTC: BSEM) has received Institutional Review Board (IRB) approval for a clinical study of AmnioWrap2™ (AW2) in treating diabetic foot ulcers (DFU). DFU is a severe complication of diabetes, leading to amputations and high healthcare costs. The study aims to evaluate the efficacy of AW2, targeting complete wound closure within 12 weeks. Secondary endpoints include time to closure, reduction in wound area and volume, and safety assessments. BioStem’s AW2 uses BioREtain™ technology, which includes unseparated amnion and chorion membranes. This trial follows promising retrospective results published in Health Science Reports. Upon successful completion, BioStem plans to seek expanded payer insurance coverage for AW2 in the DFU market.

BioStem Technologies (OTC: BSEM) announced the publication of a study in Health Science Reports, showcasing the effectiveness of its AmnioWrap2® for diabetic foot ulcers (DFUs). The study analyzed 41 subjects and compared BioStem's RE-AC, processed with the BioREtain® method, with a competitor's L-AC. Results showed that RE-AC reduced DFU areas by 67.3% over 12 weeks, compared to 52.6% for L-AC, and required fewer applications. Both methods had similar probabilities for complete wound closure. CEO Jason Matuszewski highlighted the clinical advantages and cost-efficiency of BioStem's products. Clinical studies are planned for 2024.

BioStem Technologies (OTC: BSEM) is sponsoring the MRO Better Half Dash, a popular annual NASCAR event, on May 29, 2024, at Trackhouse Motorplex in Mooresville, NC. This event features wives and girlfriends of professional racing drivers in competitive go-kart races, showcasing their talents and providing a unique spectacle for fans. Key participants include Ariana Jencik and Parker Retzlaff. Ariana, who has a background in racing and graduated from the NASCAR Technical Institute, will be competing part-time in the Late Model division. Parker Retzlaff, a prominent driver in the NASCAR Xfinity Series, praised the event for giving women a platform to shine. The event supports Darby's Warrior Support, a cause dedicated to assisting soldiers. CEO of BioStem Technologies, Jason Matuszewski, emphasized the company's pride in supporting this meaningful cause. The event will be aired on Fox Sports 1 on June 5th.

BioStem Technologies reported a record first quarter revenue of $41.9 million for 2024, marking a significant 71-fold increase from $0.6 million in Q1 2023. This impressive growth is attributed to the commercial success of AmnioWrap2®, a placental-derived allograft product. Gross profit surged to $39.7 million, representing 95% of revenue, up from 82% in the same period last year. The company also achieved a positive GAAP net income for the first time, reflecting strong financial health. Operationally, BioStem completed a two-year audit, expanded processing capacity, and enhanced its clinical capabilities. Key developments include the USPTO's prioritized examination of a critical patent and the engagement of McCoy Clinical Consulting for clinical trials.

BioStem Technologies Inc. (OTC: BSEM) will report its first quarter 2024 financial results on Tuesday, May 14, 2024. The leading biotechnology company specializes in placental derived allografts for advanced wound care. A conference call and webcast discussing the financial results and corporate updates will be held at 4:30 pm ET on the same day.

BioStem Technologies Inc. (OTC: BSEM) has been granted Prioritized Examination by the USPTO for its patent application on STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF. This patent protects BioStem's method of processing human amniotic tissue, important for wound care treatment. The global wound care dressing market is projected to grow at a CAGR of 4.16% from 2024 to 2030.

BioStem Technologies Inc. (OTC: BSEM) has hired Nick McCoy to lead the Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) clinical trials for their BioREtain Allografts. These trials aim to meet the evolving reimbursement landscape requirements and ensure patient access to their products. McCoy's extensive experience in clinical research will help accelerate the completion of trials and demonstrate the real-world benefits of BioStem's products.